Avita Medical

143 articles with Avita Medical

• AVITA Medical Announces Schedule for Six RECELL® Device Presentations at American Burn Association (ABA) 50th Annual Meeting

  4/3/2018

  Avita Medical announced new data to be presented describing clinical and cost-savings advantages of RECELL® Device in the treatment of severe burns at the American Burn Association (ABA) 50th Annual Meeting to be held from April 10 through 13, 2018 at the Hyatt Regency Chicago in Chicago.

• AVITA Medical Announces MIHS Burn Center Press Conference Regarding RECELL® Treatment of Patient with Necrotizing Fasciitis (Flesh Eating Bacteria)

  3/22/2018

  Avita Medical announced that Maricopa Integrated Health System (MIHS) Burn Center will hold a press conference today to highlight the recent treatment with RECELL® of a woman with necrotizing fasciitis, or flesh eating bacteria.

• AVITA Medical Announces Government Funded Clinical Trial of RECELL® in China

  3/19/2018

  Avita Medical announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns in China.

• AVITA Medical Announces FDA Approval of Expansion of RECELL Compassionate Use Program in Life Threatening Injuries

  2/12/2018

  This reduction in donor site skin requirements has important benefits from both clinical and health economic perspectives.

• Avita Medical Second Quarter 2018 Quarterly Cash Flow Report and Company Update

  1/31/2018

  Avita Medical announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 31 December 2017.

• Avita Medical Announces Five RECELL Abstracts Accepted for Presentation at American Burn Association (ABA) 50th Annual Meeting

  1/30/2018

  Avita Medical announced that five abstracts highlighting the compelling clinical data and health economic benefits of RECELL in the treatment of burns have been accepted for presentation at the American Burn Association 50th Annual Meeting to be held from April 10 through 13, 2018 in Chicago, Illinois.

• Avita Announces New CFO, Existing CFO Moves to Chief Administrative Officer

  12/5/2017

  Dale will be responsible for overseeing the global finance and investor relations functions, and aligning them with the company’s commercialization strategy.

• Breakthrough Medical and Pharmaceutical Funding Awarded to Consortium That Partners Avita Medical With 20 Other Organisations Across Australia

  10/27/2017

  Regenerative skin company Avita Medical is delighted to be part of Accelerating Australia, a consortium that will inject up to $2 million into a breakthrough innovation project designed to commercialise big ideas.

• Avita Medical Taps Investors for A$16.9 Million to Commercialise Its 'Spray-On Skin'

  10/11/2017

• Avita Medical Release: U.S. FDA Approves New Continued Access Protocol For The ReCell Device For Treatment Of Burn Injuries

  10/4/2017

• Avita Medical Announces Submission Of U.S. FDA Premarket Approval (PMA) Application For The Recell Device For Treatment Of Burn Injuries

  9/28/2017

• Avita Medical And BARDA Execute A $24.3 Million Contract Option

  9/21/2017

• Avita Medical Release: Research Definitively Confirms Superiority Of ReCell For Treatment Of Burn Injuries

  9/12/2017

• Avita Medical Names Erin Liberto As Chief Commercial Officer

  8/31/2017

• Avita Medical CEO Issues Shareholder Letter

  7/13/2017

• Avita Medical Release: New Randomized Trial Shows Recell Heals Donor Sites Faster

  6/20/2017

• Avita Medical Taps Former Novartis AG Exec as New CEO

  6/2/2017

• Avita Medical 's Board Show Confidence in Company By Taking Payment In Shares

  5/23/2017

• Avita Medical Announces Positive Results From Pivotal Trial

  5/18/2017

• Avita Medical Initiates Legal Proceedings To Cancel Renovacare Patent

  5/11/2017